Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Clinical trial NCT03214172 · COMPLETED

Trial details

NCT number: NCT03214172
Sponsor: Bayer
Status: COMPLETED
Study type: OBSERVATIONAL

Venous Thromboembolism

Start date: 2017-07-15
Primary completion: 2017-09-15
Enrollment: 1000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.